Kyverna Therapeutics (KYTX) Registration filing summary

Company overview and business model

• Focuses on developing cell therapies for autoimmune diseases, with a lead product candidate, mivocabtagene autoleucel (miv-cel), targeting CD19 for B-cell depletion and durable remission.

• Lead program miv-cel is in late-stage clinical development for stiff person syndrome (SPS) and generalized myasthenia gravis (gMG), both with significant unmet medical need.

• Pipeline includes additional autoimmune indications such as multiple sclerosis, rheumatoid arthritis, lupus nephritis, and systemic sclerosis, as well as next-generation CAR T technologies.

• Received RMAT and Orphan Drug Designations from FDA and EMA for key indications, supporting regulatory engagement.

• No commercial infrastructure yet; expects significant commercialization expenses if regulatory approval is obtained.

Financial performance and metrics

• As of December 31, 2025, had 60,389,893 shares of common stock outstanding.

• Net tangible book value as of December 31, 2025, was $3.85 per share; offering could increase this to $4.51 per share, with immediate dilution of $3.43 per share to new investors at an assumed offering price of $7.94.

• May continue to be a smaller reporting company if market value and revenue thresholds are not exceeded.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including R&D, capital expenditures, working capital, and administrative expenses.

• May use a portion for in-licensing, acquisitions, or investments in complementary businesses or technologies, though no current agreements exist.

• Retains broad discretion over use of proceeds; timing and allocation depend on business needs and market conditions.